Anti-inflammatory aspects of filgrastim and impact on IL-2 release

Journal of Hematotherapy and Stem Cell Research

Volumn 8, Issue SUPPL. 1, 1999, Pages

  Hartung, Thomas ^a  

^a UNIVERSITY OF KONSTANZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EXOTOXIN; GAMMA INTERFERON; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 2; LIPOPOLYSACCHARIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STAPHYLOCOCCUS TOXIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; CYTOKINE PRODUCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; REVIEW; VIRUS REPLICATION;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYTOKINES; EXFOLIATINS; FEMALE; FILGRASTIM; HIV INFECTIONS; HUMANS; INTERLEUKIN-2; LIPOPOLYSACCHARIDES; MALE; REFERENCE VALUES;

EID: 0032758166     PISSN: 15258165     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (5)

1. Hartung T, WD Docke, F Gantner, et al. (1995). Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers. Blood 85:2482.
2. Hartung T, DL Pitrak, MA Foote, et al. (1998). Filgrastim restores interleukin-2 production in blood from patients with advanced human immunodeficiency virus infection. J Infect Dis 178:686.
3. Pajkrt D, A Manten, T van der Poll, et al. (1997). Modulation of cytokine release and neutrophil function by granulocyte colony-stimulating factor during endotoxemia in humans. Blood 90:1915.
4. Hartung T, WD Doecke, D Bundschuh, et al. (1999). Effect of Filgrastim treatment on inflammatory cytokines and lymphocyte functions. Clin Pharmacol Therapeutics (in press).
5. Bernstein ZP, MM Porter, M Gould, et al. (1995). Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity. Blood 86:3287.